Physician

Ellen Redstone, MD

Study Coordinators

Danielle Schneider
Danielle.Schneider@sluhn.org

Close

The purpose of this research is to compare how FlowTriever and CDT devices work when treating pulmonary embolism, and to collect data about your pulmonary embolism treatment and follow-up. There is nothing investigational or experimental in your medical treatment if you participate in this study.

Close

• Age ≥ 18 years
• Intervention planned to begin within 72 hours of the later of either: confirmed PE diagnosis; OR if transferring from another hospital, arrival at the treating hospital
• Symptom onset within 14 days of confirmed PE diagnosis

Close

Physician

Mohamed Turki, MD

Study Coordinators

Danielle Schneider
Danielle.Schneider@sluhn.org

Close

The purpose of the study is to learn more about dupilumab (the study drug) when given over a longer duration (3 years) in patients with moderate to severe asthma that is not well controlled.

Close

• At least 18
• Patients with a physician diagnosis of asthma (according to Global Initiative for Asthma (GINA) 2021) for ≥12 months
• Treatment with medium to high dose inhaled corticosteroids (ICS) (≥250 mcg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or equivalent) in combination with a second controller (eg, long-acting beta-2 adrenergic receptor agonists (LABA), LTRA) with a stable dose ≥1 month

Close

Physician

Mohamed Turki, MD

Study Coordinators

Danielle Schneider
Danielle.Schneider@sluhn.org

Close

The purpose of the study is to investigate the effect, safety, and tolerability of the study drug for the treatment of patients with COPD, who continue to have symptoms on current treatment, and who are in need of additional treatment to their current COPD management.

Close

• Age 40 to 85
• Diagnosed with COPD for at least 1 year with moderate to severe disease
• Former or current smoker
• At least one COPD exacerbation
• Controller COPD therapy

Close